ImageneBio Inc
IMA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.03 | 4.09 | 2.73 | 0.98 |
| FCF Yield | -0.44% | -1.42% | -0.66% | -0.89% |
| EV / EBITDA | -82.67 | -76.69 | -75.94 | -83.88 |
| Quality | ||||
| ROIC | -6.84% | -8.54% | -9.36% | -8.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.08 | 1.24 | 1.23 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 67.60% | -68.72% | 29.96% | 28.51% |
| Safety | ||||
| Net Debt / EBITDA | 6.01 | 3.25 | 2.64 | 3.20 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -832.76 | 0.00 | -1,540.00 |